Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

BI 10773 add-on to Metformin in Patients With Type 2 Diabetes

ClinicalTrials.gov ID: NCT00749190

Public ClinicalTrials.gov record NCT00749190. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 4, 2026, 12:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Randomized, Parallel Group Safety, Efficacy, and Pharmacokinetics Study of BI 10773 (1 mg, 5 mg, 10 mg, 25 mg, and 50 mg) Administered Orally Once Daily Over 12 Weeks Compared Double Blind to Placebo With an Additional Open-label Sitagliptin Arm in Type 2 Diabetic Patients With Insufficient Glycemic Control Despite Metformin Therapy

Study identification

NCT ID
NCT00749190
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
495 participants

Conditions and interventions

Interventions

  • BI 10773 Drug
  • placebo Drug
  • sitagliptin Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 79 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2008
Primary completion
Sep 30, 2009
Completion
Not listed
Last update posted
Jun 12, 2014

Started 2008

United States locations

U.S. sites
19
U.S. states
10
U.S. cities
18
Facility City State ZIP Site status
1245.10.10026 Boehringer Ingelheim Investigational Site Chula Vista California
1245.10.10001 Boehringer Ingelheim Investigational Site Mission Viejo California
1245.10.10011 Boehringer Ingelheim Investigational Site Pasadena California
1245.10.10028 Boehringer Ingelheim Investigational Site Spring Valley California
1245.10.10027 Boehringer Ingelheim Investigational Site Walnut Creek California
1245.10.10004 Boehringer Ingelheim Investigational Site Clearwarter Florida
1245.10.10021 Boehringer Ingelheim Investigational Site Melbourne Florida
1245.10.10005 Boehringer Ingelheim Investigational Site Miami Florida
1245.10.10019 Boehringer Ingelheim Investigational Site Miami Florida
1245.10.10024 Boehringer Ingelheim Investigational Site Saint Cloud Florida
1245.10.10014 Boehringer Ingelheim Investigational Site Roswell Georgia
1245.10.10016 Boehringer Ingelheim Investigational Site Staten Island New York
1245.10.10009 Boehringer Ingelheim Investigational Site Shelby North Carolina
1245.10.10006 Boehringer Ingelheim Investigational Site Wadsworth Ohio
1245.10.10023 Boehringer Ingelheim Investigational Site Norristown Pennsylvania
1245.10.10010 Boehringer Ingelheim Investigational Site Clemson South Carolina
1245.10.10015 Boehringer Ingelheim Investigational Site Dallas Texas
1245.10.10012 Boehringer Ingelheim Investigational Site Temple Texas
1245.10.10025 Boehringer Ingelheim Investigational Site Federal Way Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 97 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00749190, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 12, 2014 · Synced May 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00749190 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →